The bidirectional association among female hormone‐related cancers: breast, ovary, and uterine corpus

Chen, Min Chi; Lee, Kuan Der; Lu, Chang; Wang, Ting Yao; Huang, Shu‐Mei; Chen, Chao Yu

doi:10.1002/cam4.1473

Cited by 10 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast, ovarian, and uterine corpus cancers are common female cancers and categorized as hormone-related diseases. The recent population-based study carried by Chen et al in Taiwan to test the hypothesis of bidirectional associations among these cancers found similar results to our study [15]. Using a cohort of 110,112 cases with primary female cancers including uterine corpus cancer (11,146 cases), ovarian cancer (12,139 cases), or breast cancer (86,827 cases) from the Taiwan Cancer Registry from 1979 to 2008, the pairwise risks of second cancer among uterine corpus, ovary, and breast cancer cases were evaluated.…”

Section: Discussionsupporting

confidence: 92%

“…If we evaluate a 20-years disease free survival instead of a 3-5 year period, considering that the tumors can develop several years after ending the treatment with tamoxifen, our data support the fact that the survival rate at those two time periods is significatively different, decreasing overtime for women who underwent this treatment (Figure 1). By continuing to studying the long term survival at 20 years, we were able to evaluate more precisely the long-term effect of tamoxifen, as already suggested in other studies [5,15,[19][20][21][22]. Based on these data, we believe that it is neccesary to create an increased awareness among gynecological health providers.…”

Section: Discussionmentioning

confidence: 57%

See 1 more Smart Citation

https://researchopenworld.com/tamoxifen-uterine-corpus-cancer-and-breast-cancer/#

2018

Cancer Stud Ther J

View full text Add to dashboard Cite

Background: In 2017 we described 5-year histological and disease-free survival data from a series of 429 patients with cancers of the uterine corpus (UCC), observing similar percentages to those described in the medical literature. The only difference we found with other published studies was a slightly lower percentage of serous carcinomas (SC) in the Western countries, but similar to the 3% of all SC in Japan [1]. The objective of this study was to evaluate the prognosis of uterine corpus cancer and the influence of tamoxifen on the histological types of uterine body cancer, and their long-term survival (20 year follow-up). Methods: Two series of patients were included in this study: [1] 429 patients with uterine corpus cancer and [2] 1385 patients with breast cancer. The second group included 1057 patients who had been treated with tamoxifen and 328 who had not been treated. All women had been diagnosed at the same Hospital (General University Hospital of Vigo). Crossing both series, we observed that 51 women were diagnosed with both uterine and breast neoplasias. Previously, we had excluded those cases of breast cancer (n = 1051) at the time of closing the data collection as we were not certain whether or not they had received hormonal treatment. We compared histological types of corpus uterine cancer for women with and without a prior diagnosis of breast cancer. Age of diagnosis, uterine tumor stage, histological cell type, histological grade, treatment and time 20 year free disease were analyzed using Kaplan-Meier and log-rank test analysis. Results: Women diagnosed with UCC with a personal history of a previous breast cancer treated with tamoxifen had UCC with significantly more undifferentiated histological types than those with UCC who had not received tamoxifen: with a significantly higher proportion of uterine papillary serous carcinomas (3.2 % vs. 1.9 %), clear cell (6.4 % vs. 3.7 %), indifference carcinoma (3.2% vs. 0.8%) and sarcomas (9.7% vs. 3,7%) compared to those without a personal history of breast cancer (p < 0.001). There were no differences with regards FIGO Stage uterine corpus cancer with and without breast cancer history (p > 0.05). The 20-years free of disease survival in patients with endometrial adenocarcinoma was significantly decreased in women with tamoxifen breast cancer history (p = 0.04). Conclusions: In this study, our data showed that women with uterine corpus cancer who had a personal history of breast cancer treated with tamoxifen had an increased risk of developing more aggressive UCCs and a lower 20-years free of disease survival. The odds ratio was 2.4. We think that a regular uterine endometrial and myometrial follow-up in the very long term is necessary in women diagnosed with breast cancer and treated with tamoxifen.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 57%

https://researchopenworld.com/tamoxifen-uterine-corpus-cancer-and-breast-cancer/#

2018

Cancer Stud Ther J

View full text Add to dashboard Cite

show abstract

“…A bi-directional link has also been found between corpus uteri and breast and between ovary and corpus uteri, which share hormonal, genetic and etiologic factors [32][33][34]. These associations have also been found in Taiwan and were strongest within the first 5 years after the FPC [35].…”

Section: Discussionmentioning

confidence: 81%

The epidemiology of multiple primary cancers in Belgium (2004–2017): Incidence, proportion, risk, stage and impact on relative survival estimates

Macq¹,

Silversmit²,

Verdoodt³

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background As both life expectancy and cancer survival improve, the incidence of multiple primary cancer has augmented and is expected to further increase. This study describes for the first time the epidemiology of multiple invasive tumours in Belgium. Methods This nationwide study, based on all cancers diagnosed between 2004 and 2017 in Belgium, describes the proportion of multiple primary cancer, its evolution over time, the impact of inclusion or exclusion of multiple primary cancer on relative survival estimates, the risk of developing a second primary cancer, and the difference in stage between first and second primary cancer for the same patient. Results The proportion of multiple primary cancer increases with age, varies across cancer sites (from 4% for testis cancer to 22.8% for oesophageal cancer), is higher in men than in women, and has linearly increased over time. The inclusion of multiple primary cancer resulted in smaller 5-year relative survival and this impact is more pronounced in cancer sites with high relative survival. Patients with a first primary cancer have an increased risk to develop a new primary cancer compared to the population without a previous cancer history (1.27 and 1.59 times higher in men and women, respectively) and this risk depends on cancer site. Second primary cancers are associated with more advanced stages and more unknown stages than the corresponding first cancer diagnosis. Conclusions This study describes multiple primary cancer according to several measures (proportion, standardised incidence ratio for an second primary cancer, impact of multiple primary cancer on relative survival and differences according to stage) for the first time in Belgium. The results are based on data of a population-based cancer registry with a relatively recent onset (2004).

show abstract

“…In terms of data source, three studies used hospital-based data ( 61 , 63 , 74 ), and the others used population-based data. A total of 16 studies mentioned that the IARC definition was used for defining the second primary cancers ( 10 , 12 , 14 – 17 , 63 , 66 – 69 , 71 – 73 , 77 , 79 ), but the remaining studies did not mention this. In general, the studies included in this systematic review cover data from 22 countries: Japan, South Korea, Taiwan, Singapore, Turkey, Israel, United Kingdom, Finland, Denmark, Sweden, Norway, Germany, France, Greece, Netherlands, Switzerland, Spain, Slovenia, Italy, Iceland, Canada, and Australia ( Figure 2 ).…”

Section: Resultsmentioning

confidence: 99%

“…( 66 ), which was conducted on men. The methodological quality of the included articles was evaluated as high, except for the articles that were prone to misclassification bias ( 61 , 68 ) and/or selection bias ( 15 , 17 , 59 , 61 , 62 , 70 , 73 , 74 , 77 ).…”

Section: Resultsmentioning

confidence: 99%

Risk of second primary cancer among breast cancer patients: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

ObjectivesThe aim of this study was to estimate the extra risk of second primary cancer among breast cancer patients.Methods and materialsThis is a systematic review. A comprehensive search of literature was performed in PubMed, Web of Science, Cochrane library, and Scopus. The search included all published studies up to October 2022. This systematic review included studies published in the English language that reported the risk of second primary non-breast cancer [i.e., standardized incidence ratio (SIR)] among breast cancer patients older than 15 years. After evaluating the methodological quality of the selected studies, SIRs were pooled with consideration of heterogeneity among studies. The estimates were pooled by age and time since the diagnosis of primary breast cancer for both sexes (male and female). Age was categorized based on before 50 years and after 50 years, and time was categorized as duration of less than and more than 10 years, respectively.ResultsFrom 2,484 articles, 30 articles were eligible for inclusion in the systematic review and meta-analysis. The studies varied in terms of population, number of cases, study design, setting, and year of implementation of the research. The estimated SIR for men and women was 1.28 (95% CI: 1.18, 1.38) and 1.27 (95% CI: 1.15, 1.39), respectively. Women diagnosed with breast cancer before menopause [SIR: 1.52 (95% CI: 1.34, 1.71) vs. 1.21 (95% CI: 1.08, 1.34)] as well as women after 10 years since their breast cancer diagnosis [1.33 (95% CI: 1.22, 1.431) vs. 1.24 (95% CI: 1.10, 1.37)] were at a higher risk of developing second primary cancer. Among men, while there were no differences in risk based on age, with the increase of time, the risk of second primary cancer was reduced [SIR: 1.22 (95% CI: 1.12, 1.33) vs. 1.00 (95% CI: 0.79, 1.22)].ConclusionThere is an extra risk of second primary cancer among breast cancer patients. The extra risk should be considered for further screening and preventive measures among this population.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=336062, identifier (CRD42022336062).

show abstract

The bidirectional association among female hormone‐related cancers: breast, ovary, and uterine corpus

Cited by 10 publications

References 28 publications

https://researchopenworld.com/tamoxifen-uterine-corpus-cancer-and-breast-cancer/#

https://researchopenworld.com/tamoxifen-uterine-corpus-cancer-and-breast-cancer/#

The epidemiology of multiple primary cancers in Belgium (2004–2017): Incidence, proportion, risk, stage and impact on relative survival estimates

Risk of second primary cancer among breast cancer patients: A systematic review and meta-analysis

Contact Info

Product

Resources

About